Glenmark vs Biocon: share price, P/E, ROE and financials compared
Glenmark Pharmaceuticals
Biocon
Glenmark and Biocon at a glance
Glenmark and Biocon are both listed in Healthcare. Glenmark is the larger by market cap, at ₹73,096 Cr against ₹59,794 Cr for Biocon (1.2 times as large). On valuation, Glenmark has the lower P/E (50.4× against 122.5×), while Biocon has the lower price-to-book (1.73× against 6.52×). On returns and margins, Glenmark has the higher ROCE (16.2% against 2.8%) and the higher ROE (14.0% against 1.0%), while Biocon has the higher operating margin (19.4% against 18.0%). Over three years, Glenmark has faster 3-year profit growth (+66.1% against −5.9% a year), while Biocon has faster 3-year sales growth (+15.3% against +13.5% a year). Glenmark carries less debt for its equity, with a debt-to-equity of 0.13× against 0.42×.
Key metrics, side by side
| Metric | GlenmarkGLENMARK | BioconBIOCON |
|---|---|---|
| Price (₹) | 2,590.00 | 365.10 |
| Market cap (₹ Cr) | 73,096 | 59,794 |
| P/E | 50.4× (the lower figure, shaded) | 122.5× |
| P/B | 6.52× | 1.73× (the lower figure, shaded) |
| Dividend yield, trailing | 0.10% | 0.14% |
| ROE | 14.0% (the higher figure, shaded) | 1.0% |
| ROCE | 16.2% (the higher figure, shaded) | 2.8% |
| Operating margin (OPM) | 18.0% | 19.4% (the higher figure, shaded) |
| Net margin (NPM) | 9.2% (the higher figure, shaded) | 2.6% |
| Sales CAGR 3Y | +13.5% | +15.3% (the higher figure, shaded) |
| Profit CAGR 3Y | +66.1% (the higher figure, shaded) | −5.9% |
| Debt to equity | 0.13× (the lower figure, shaded) | 0.42× |
| Interest cover | 10.5× (the higher figure, shaded) | 1.5× |
| Net profit TTM (₹ Cr) | 1,451 | 452 |
| 1Y return | +34.5% (the higher figure, shaded) | −4.9% |
| Promoter holding | 46.65% | – |
Glenmark vs Biocon: common questions
Which is bigger, Glenmark or Biocon?
By market cap, Glenmark is bigger at ₹73,096 Cr, against ₹59,794 Cr for Biocon (prices as of 6 Nov 2026). Net profit over the last twelve months was ₹1,451 Cr for Glenmark and ₹452 Cr for Biocon.
Which has a lower P/E ratio, Glenmark or Biocon?
Glenmark trades at a P/E of 50.4× and Biocon at 122.5×. Glenmark has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Glenmark or Biocon?
Glenmark reports a return on equity of 14.0% and Biocon 1.0%. Glenmark has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Glenmark or Biocon?
Over the last three years: Sales grew +13.5% a year at Glenmark and +15.3% at Biocon, so Biocon grew sales faster; profit grew +66.1% a year at Glenmark and −5.9% at Biocon, so Glenmark grew profit faster. Past growth doesn’t predict future growth.